-
Product Insights
Brain Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Brain Cancer - Drugs In Development, 2023’, provides an overview of the Brain Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Brain Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Growth Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Growth Disorders - Drugs In Development, 2023’, provides an overview of the Growth Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Growth Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Idiopathic Short Stature – Drugs In Development, 2023
Global Markets Direct’s, ‘Idiopathic Short Stature - Drugs In Development, 2023’, provides an overview of the Idiopathic Short Stature pipeline landscape. The report provides comprehensive information on the therapeutics under development for Idiopathic Short Stature, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Growth Hormone Deficiency – Drugs In Development, 2023
Global Markets Direct’s, ‘Growth Hormone Deficiency - Drugs In Development, 2023’, provides an overview of the Growth Hormone Deficiency pipeline landscape. The report provides comprehensive information on the therapeutics under development for Growth Hormone Deficiency, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Ependymoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Ependymoma - Drugs In Development, 2023’, provides an overview of the Ependymoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ependymoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Prader-Willi Syndrome (PWS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Prader-Willi Syndrome (PWS) - Drugs In Development, 2023’, provides an overview of the Prader-Willi Syndrome (PWS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibutamoren Mesylate in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibutamoren Mesylate in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibutamoren Mesylate in Metabolic Dysfunction-Associated Steatotic Liver...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibutamoren Mesylate in Growth Hormone Deficiency
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibutamoren Mesylate in Growth Hormone Deficiency report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibutamoren Mesylate in Growth Hormone Deficiency Drug Details: Ibutamoren...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibutamoren Mesylate in Non Alcoholic Fatty Liver Disease (NAFLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibutamoren Mesylate in Non Alcoholic Fatty Liver Disease (NAFLD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibutamoren Mesylate in Non Alcoholic Fatty Liver...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NUV-868 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NUV-868 in Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NUV-868 in Ovarian Cancer Drug Details:NUV-868 is under development for the treatment of...